Patents by Inventor Thomas R. Caulfield
Thomas R. Caulfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240092831Abstract: In some embodiments, the present disclosure provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula (II) as described herein, or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising the compound of Formula (I) or Formula (II), and methods of treating cancer using the compound of Formula (I) or Formula (II) are also provided.Type: ApplicationFiled: October 9, 2020Publication date: March 21, 2024Inventors: Asher Alban Akmal Chanan-Khan, Aneel Paulus, Thomas R. Caulfield
-
Publication number: 20240058318Abstract: Methods and material for treating cancer (e.g., estrogen receptor negative (ER?) and estrogen receptor positive (ER+) breast cancer) are described herein. For example, methods and materials for targeting degradation of protein kinase C type beta (PKC?1) polypeptides in mammals with ER? cancers are described.Type: ApplicationFiled: December 10, 2021Publication date: February 22, 2024Inventors: Matthew P. Goetz, Thomas R. Caulfield, John Randolph Hawse, IV
-
Publication number: 20230310419Abstract: The present application provides methods and compositions for treating cancer, for example, renal cell carcinoma, melanoma, ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancer, and more particularly to using an inhibitor of a stearoyl-Coenzyme A desaturase 1 (SCD1) enzyme in combination with a checkpoint inhibitor to treat these disorders.Type: ApplicationFiled: January 26, 2023Publication date: October 5, 2023Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Christina Von Roemeling, Han W. Tun, Thomas R. Caulfield, Yon Son Betty Kim
-
Publication number: 20230128765Abstract: The present disclosure relates to compounds for activating the enzymatic activity of an E3 ubiquitin ligase and methods for treating a disease or disorder in a subject with diminished E3 ubiquitin ligase enzymatic activity. In some embodiments, the present disclosure provides a compound of Formula I or a compound of Formula II. or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 16, 2022Publication date: April 27, 2023Applicant: Mayo Foundation for Medical Education and ResearchInventors: Wolfdieter Springer, Fabienne C. Fiesel, Thomas R. Caulfield
-
Patent number: 11596629Abstract: The present application provides methods and compositions for treating cancer, for example, renal cell carcinoma, melanoma, ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancer, and more particularly to using an inhibitor of a stearoyl-Coenzyme A desaturase 1 (SCD1) enzyme in combination with a checkpoint inhibitor to treat these disorders.Type: GrantFiled: February 28, 2018Date of Patent: March 7, 2023Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Christina Von Roemeling, Han W. Tun, Thomas R. Caulfield, Yon Son Kim
-
Publication number: 20220411389Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: ApplicationFiled: April 5, 2022Publication date: December 29, 2022Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Patent number: 11401255Abstract: The present disclosure relates to compounds for activating the enzymatic activity of an E3 ubiquitin ligase and methods for treating a disease or disorder in a subject with diminished E3 ubiquitin ligase enzymatic activity. In some embodiments, the present disclosure provides a compound of Formula (I) or a compound of Formula (II) or pharmaceutically acceptable salts thereof.Type: GrantFiled: July 28, 2017Date of Patent: August 2, 2022Assignee: Mayo Foundation for Medical Education and ResearchInventors: Wolfdieter Springer, Fabienne C. Fiesel, Thomas R. Caulfield
-
Patent number: 11325892Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: GrantFiled: May 24, 2019Date of Patent: May 10, 2022Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Publication number: 20200061055Abstract: The present application provides methods and compositions for treating cancer, for example, renal cell carcinoma, melanoma, ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancer, and more particularly to using an inhibitor of a stearoyl-Coenzyme A desaturase 1 (SCD1) enzyme in combination with a checkpoint inhibitor to treat these disorders.Type: ApplicationFiled: February 28, 2018Publication date: February 27, 2020Applicant: Mayo Foundation for Medical Education and ResearchInventors: Christina Von Roemeling, Han W. Tun, John A. Copland, III, Thomas R. Caulfield, Yon Son Betty Kim
-
Publication number: 20190345123Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: ApplicationFiled: May 24, 2019Publication date: November 14, 2019Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Publication number: 20190169158Abstract: The present disclosure relates to compounds for activating the enzymatic activity of an E3 ubiquitin ligase and methods for treating a disease or disorder in a subject with diminished E3 ubiquitin ligase enzymatic activity. In some embodiments, the present disclosure provides a compound of Formula (I) or a compound of Formula (II) or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: July 28, 2017Publication date: June 6, 2019Applicant: Mayo Foundation for Medical Education and ResearchInventors: Wolfdieter Springer, Fabienne C. Fiesel, Thomas R. Caulfield
-
Patent number: 10301273Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: GrantFiled: August 7, 2015Date of Patent: May 28, 2019Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Publication number: 20170226073Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: ApplicationFiled: August 7, 2015Publication date: August 10, 2017Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Patent number: 9464093Abstract: This document relates to compounds and compositions useful for treating cancers, such as brain and nervous system cancers.Type: GrantFiled: October 11, 2013Date of Patent: October 11, 2016Assignees: Mayo Foundation for Medical Education and Research, Osaka UniversityInventors: Han W. Tun, Takehiko Yoshimitsu, Daisuke Shigeoka, Takuma Kamon, Zhimin Li, Yushi Qiu, Thomas R. Caulfield
-
Publication number: 20150274742Abstract: This document relates to compounds and compositions useful for treating cancers, such as brain and nervous system cancers.Type: ApplicationFiled: October 11, 2013Publication date: October 1, 2015Inventors: Han W. Tun, Takehiko Yoshimitsu, Daisuke Shigeoka, Takuma Kamon, Zhimin Li, Yushi Qiu, Thomas R. Caulfield
